Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma.
about
ALK Signaling and Target Therapy in Anaplastic Large Cell LymphomaAnaplastic lymphoma kinase: signalling in development and diseaseEvaluation of EML4-ALK fusion proteins in non-small cell lung cancer using small molecule inhibitorsLoss of protein inhibitors of activated STAT-3 expression in glioblastoma multiforme tumors: implications for STAT-3 activation and gene expressionOverexpression of PIAS3 suppresses cell growth and restores the drug sensitivity of human lung cancer cells in association with PI3-K/Akt inactivationRegulation of Natural Killer Cell Function by STAT3Structural basis for the recognition of nucleophosmin-anaplastic lymphoma kinase oncoprotein by the phosphotyrosine binding domain of Suc1-associated neurotrophic factor-induced tyrosine-phosphorylated target-2Targeting signal-transducer-and-activator-of-transcription-3 for prevention and therapy of cancer: modern target but ancient solutionSTAT3 as a therapeutic target in head and neck cancerIdentification and characterization of a nuclear interacting partner of anaplastic lymphoma kinase (NIPA)Inhibition of STAT3 dimerization and acetylation by garcinol suppresses the growth of human hepatocellular carcinoma in vitro and in vivo.Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy.The heterogeneous landscape of ALK negative ALCL.Stat3 activates the receptor tyrosine kinase like orphan receptor-1 gene in chronic lymphocytic leukemia cells.STAT3- and DNA methyltransferase 1-mediated epigenetic silencing of SHP-1 tyrosine phosphatase tumor suppressor gene in malignant T lymphocytesJAK2 V617F detected in two B-cell chronic lymphocytic leukemia patients without coexisting Philadelphia chromosome-negative myeloproliferative neoplasms: A report of two cases.STAT3 is constitutively phosphorylated on serine 727 residues, binds DNA, and activates transcription in CLL cells.Programmed cell death-10 enhances proliferation and protects malignant T cells from apoptosis.Negative regulation of signal transducer and activator of transcription-3 signalling cascade by lupeol inhibits growth and induces apoptosis in hepatocellular carcinoma cells.The heat shock protein-90 co-chaperone, Cyclophilin 40, promotes ALK-positive, anaplastic large cell lymphoma viability and its expression is regulated by the NPM-ALK oncoprotein.Thymoquinone inhibits proliferation, induces apoptosis and chemosensitizes human multiple myeloma cells through suppression of signal transducer and activator of transcription 3 activation pathwayInitial solid tumor testing (stage 1) of AZD1480, an inhibitor of Janus kinases 1 and 2 by the pediatric preclinical testing program.ALK-driven tumors and targeted therapy: focus on crizotinibInterleukin-6 and new strategies for the treatment of cancer, hyperproliferative diseases and paraneoplastic syndromes.Anaplastic lymphoma kinase is a dependence receptor whose proapoptotic functions are activated by caspase cleavage.Stat proteins and oncogenesis.Nucleophosmin/anaplastic lymphoma kinase (NPM/ALK) oncoprotein induces the T regulatory cell phenotype by activating STAT3Extranodal NK/T-cell lymphoma: toward the identification of clinical molecular targetsγ-Tocotrienol is a novel inhibitor of constitutive and inducible STAT3 signalling pathway in human hepatocellular carcinoma: potential role as an antiproliferative, pro-apoptotic and chemosensitizing agent.Expression and oncogenic role of Brk (PTK6/Sik) protein tyrosine kinase in lymphocytes.IL-2R common gamma-chain is epigenetically silenced by nucleophosphin-anaplastic lymphoma kinase (NPM-ALK) and acts as a tumor suppressor by targeting NPM-ALK.Molecular targets in therapy for human soft-tissue and bone sarcomas.Calyculin A reveals serine/threonine phosphatase protein phosphatase 1 as a regulatory nodal point in canonical signal transducer and activator of transcription 3 signaling of human microvascular endothelial cells.Anaplastic lymphoma kinase proteins in growth control and cancer.Persistent activation of STAT3 by PIM2-driven positive feedback loop for epithelial-mesenchymal transition in breast cancer.Evaluation of enrichment techniques for mass spectrometry: identification of tyrosine phosphoproteins in cancer cellsDetection of protein tyrosine-kinase (PTK) gene expression pattern in normal and malignant T lymphocytes by combined PTK-specific polymerase chain reaction and parallel denaturing gradient gel electrophoresis.Prognostic value of protein inhibitor of activated STAT3 in breast cancer patients receiving hormone therapy.Signal transducers and activators of transcription: insights into the molecular basis of oral cancer.Pathobiology of ALK+ anaplastic large-cell lymphoma.
P2860
Q21129306-259E8BA0-7F5D-473F-A03E-E901FDAA284BQ24312329-7ACF5F76-7C16-43AC-869F-0E7946992E1AQ24595585-A5297F79-79E0-4122-BA75-2AA45C45810FQ24619748-D027096A-6F3C-4494-8B18-E97558A11DA9Q24678516-EBF21E67-0574-415B-9870-FE29639F5538Q26752551-522BD769-9312-48AD-9170-AEA6BDF02CBBQ27661453-AC1960F8-9D48-431A-82C1-60C6EFA9F216Q28291780-046E8065-1EEE-47F4-9EB6-058398D64E88Q28299368-B41121B8-9494-46D4-8BFC-84B4CC28FA5AQ28588852-9A0F5ED9-DAE5-4169-9230-51192B6C1AEBQ30576918-B2C7B198-9F3A-4718-932C-9E8A4B500DDEQ33293980-1BCA16CB-4C74-4F5E-9453-F72B2FCEA26CQ33567012-E3985316-D19E-4586-919E-10C9CD89D1E6Q33649606-A554FCC9-E8CE-4839-8930-859202EDB1C6Q33784496-72072A78-5F0B-4480-95AF-3A1505FB3526Q33843882-64D5E1BE-836C-4B26-AF68-C9752A64EDCEQ34052726-51443FCD-1EAF-40A0-99DB-3AD2227B1380Q34154516-88EEB095-C3FD-42EE-9923-87BAC4794F61Q34283730-E86E683E-CCA5-4709-B2D6-83E0455F1DFDQ34297784-2E10FA30-C369-453F-8754-D43A3E8C1FAEQ34342251-F5708B6B-C7B9-472D-A92A-D298248769F4Q34361391-1F8ECEA6-DF1B-4DF6-B537-CF727EA2E254Q34414378-6D80F0B6-B130-49FC-A10A-D4368203D77AQ34440657-20D21FAE-60C3-4CF5-BD7F-6DF77AA788AEQ34552993-49DE0A86-89EA-409B-B16C-4EFEE2CD9055Q34627064-035D3F42-6DFE-4584-9ED2-2DBA0A78AFC1Q34773094-5AAE4F70-F4BA-429B-B758-50B90CAE3C26Q34898306-F50F5D14-FC1A-415E-83B0-62D651781125Q34919598-C1EB8A61-D9DC-4A72-A3AC-87182D07DAD6Q35088231-45ECE3F9-1009-4F09-A8AC-B6C505D99A80Q35123227-B4F05AE4-3F33-4D14-9924-1C2667AC276BQ35142828-B108C0F9-EED0-48A5-8F93-4D4FCDD9A4A3Q35743848-54983B2B-80E1-40E5-AA48-3B40168998B8Q35750450-2E47C063-1CD6-4DC4-92D3-D25ADEEA495BQ35754295-9E75CCF4-99A4-4369-A468-180388F1CBE7Q35789634-223CA8EA-07DB-4043-8BA0-E93C7E22E6E2Q35870285-1EE32E8C-6B3B-490C-97F9-46A83D77D81FQ35894524-38C9B7B5-18EC-4836-8E30-4E59562C8643Q35911353-C89696FE-F9E3-4257-8F66-012FBA5EBB91Q36007756-981935E7-F404-4727-89D9-ABDF196CCCE8
P2860
Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Multilevel dysregulation of ST ...... positive T/null-cell lymphoma.
@en
type
label
Multilevel dysregulation of ST ...... positive T/null-cell lymphoma.
@en
prefLabel
Multilevel dysregulation of ST ...... positive T/null-cell lymphoma.
@en
P2093
P1476
Multilevel dysregulation of ST ...... positive T/null-cell lymphoma.
@en
P2093
David F Carpentieri
Liquan Xue
Mariusz A Wasik
Miroslaw Majewski
Niels Odum
Puthryaveett N Raghunath
Qian Zhang
Stephan Morris
Tomasz Skorski
P304
P356
10.4049/JIMMUNOL.168.1.466
P407
P577
2002-01-01T00:00:00Z